At its first meeting under the new administration, the US Centers for Disease Control and Prevention’s (CDC) Advisory ...

ACIP votes to expand recommendation for Pfizer’s RSV vaccine Abrysvo to include adults aged 50 to 59 at increased risk of disease: New York Saturday, April 19, 2025, 10:00 Hrs [ ...

US flu activity declined steadily again last week, with rates of influenza-like illness (ILI) dropping further and staying ...

US hospital data from 2018 through 2022 shows carbapenem-resistant Acinetobacter baumanii accounted for more than one third of all Acinetobacter nfections.

Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in ...

On Wednesday, the Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of ...

The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a ...

Pfizer (NYSE:PFE) recently received a CDC recommendation for wider use of its RSV vaccine, ABRYSVO, in adults aged 50-59 at ...

A year after narrowing its recommendation for who should use vaccines to defend against respiratory syncytial virus (RSV), a ...

The Trump administration is considering eliminating dozens of programs at HHS amid a mass reorganization of the agency.

The committee endorsed lowering the age at which some people can receive RSV vaccines, but stopped short of recommending ...